Literature DB >> 3837120

Diphtheria in Afghanistan--review of 155 cases.

M Singh, A Saidali, A Bakhtiar, L S Arya.   

Abstract

During the 3-year study period, 155 culture-positive cases of diphtheria were reviewed at the Institute of Child Health, Kabul. They comprised 0.6% of hospital admissions due to medical disorders in our institute. About 80% of patients belonged to an age group of 1-10 years and only two patients were less than 1 year old. The male to female ratio was 1.3:1. There was no history of previous vaccination against diphtheria in 96.7% of patients. In the majority of patients faucial diphtheria was diagnosed (77.4%), followed by laryngeal (16.1%) an combined pharyngolaryngeal (6.5%). Clinical presentation was with a mild to moderate degree of fever, sore throat, cervical lymphadenopathy, toxaemia, tachycardia and a characteristic thick greyish-white membrane. The main early complications were laryngeal obstruction (35), myocarditis (18), shock (3), polyneuritis (3) and renal failure (2). The overall case fatality rate was 19.3%. Prognosis was unfavourable in patients with laryngeal diphtheria when there was a delay of more than 4 days before reaching the hospital and if there was a delay in relieving laryngeal obstruction by tracheostomy. Outcome was unrelated to the age of the patient.

Entities:  

Mesh:

Year:  1985        PMID: 3837120

Source DB:  PubMed          Journal:  J Trop Med Hyg        ISSN: 0022-5304


  3 in total

1.  Prognosis in patients with diphtheric myocarditis and bradyarrhythmias: assessment of results of ventricular pacing.

Authors:  B A Stockins; F T Lanas; J G Saavedra; J A Opazo
Journal:  Br Heart J       Date:  1994-08

Review 2.  Diphtheria: changing patterns in the developing world and the industrialized world.

Authors:  A M Galazka; S E Robertson
Journal:  Eur J Epidemiol       Date:  1995-02       Impact factor: 8.082

Review 3.  Epidemiological Impact of Myocarditis.

Authors:  Ainoosh Golpour; Dimitri Patriki; Paul J Hanson; Bruce McManus; Bettina Heidecker
Journal:  J Clin Med       Date:  2021-02-05       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.